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Background: mRNA expression data from next generation sequencing platforms is obtained in the form of counts
per gene or exon. Counts have classically been assumed to follow a Poisson distribution in which the variance is
equal to the mean. The Negative Binomial distribution which allows for over-dispersion, i.e., for the variance to be
greater than the mean, is commonly used to model count data as well.
Results: In mRNA-Seq data from 25 subjects, we found technical variation to generally follow a Poisson distribution
as has been reported previously and biological variability was over-dispersed relative to the Poisson model. The
mean-variance relationship across all genes was quadratic, in keeping with a Negative Binomial (NB) distribution.
Over-dispersed Poisson and NB distributional assumptions demonstrated marked improvements in goodness-of-fit
(GOF) over the standard Poisson model assumptions, but with evidence of over-fitting in some genes. Modeling of
experimental effects improved GOF for high variance genes but increased the over-fitting problem.
Conclusions: These conclusions will guide development of analytical strategies for accurate modeling of variance
structure in these data and sample size determination which in turn will aid in the identification of true biological
signals that inform our understanding of biological systems.Background
Next generation sequencing is a tool that is revolutioniz-
ing scientific research with its unprecedented depth of
coverage, accuracy, precision, and the ability to link gene
expressions with phenotype. The Illumina Genome
Analyzer (GA), originally by Solexa, enables interroga-
tion of mRNA expression via the mRNA Sequencing
protocol. There are several reports on quality assess-
ments of next generation sequencing and comparisons
with microarray gene expression [1,2]. Biological signal
has been evaluated in single biological replicates of cell
lines or tissue samples from this platform [3-5]. Anders
and Huber report on variation in pools of two fruit fly
embryos [6]; however, to date there is no thorough re-
port on the functional form of variance in variability in
mRNA Sequencing data from true human biological
replicates. Thus, we evaluated the structure of biological
variability and statistical modeling strategies useful for* Correspondence: oberg.ann@mayo.edu
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reproduction in any medium, provided the ordetermining differential expression in mRNA-Seq data
with true biological replicates.
First we describe some distributional background. The
Poisson distribution is commonly assumed when model-
ing count data. This distribution considers each individ-
ual piece of mRNA to be a random draw from a large
collection of pieces of mRNA with some probability vec-
tor describing the relative proportion across all possible
mRNA pieces. A piece could refer to a particular exon
or gene according to the researcher’s interest. The Pois-
son distribution appears to describe well the variation
observed between two technical replicates of the same
specimen, i.e., two aliquots of the same library allocated
to two lanes on a flow cell [3-5]. The mean, μ, and vari-
ance are expected to be equal when sampling from a
Poisson distribution, i.e., Var(y) = μ.
Biological replication adds another level of variability
to the observed data. Biological variability is that due to
inter-individual differences between human or animal
subjects, for example, which cause the probability vector
describing the distribution of mRNA strands to differ
between subjects. Thus, when count data are observed
in multiple biological replicates, the observed variance isLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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pieces. This results in the observed variance being larger
than expected under the Poisson distribution. That is,
the variance is larger than the mean. This scenario is
termed “over-dispersion” [7].
In the simplest case, variance increases as a linear func-
tion of the mean, i.e., the variance is a constant multiplied
by the mean, Var(y) = kμ. We denote this as the over-
dispersed (OD) Poisson throughout and model para-
meters can be estimated via quasi-likelihood methods. A
more sophisticated model assumes the within-specimen
(technical) variation follows a Poisson distribution and
the between-specimen mean values follow a gamma dis-
tribution. This gives rise to the negative binomial (NB)
distribution in which the variance increases as a quadratic
function of the mean, i.e., Var(y) = μ+φμ2 [7].
Our goal in the present work was to characterize the
mean-variance relationship in mRNA Seq data in order to
guide the choice of distributional assumptions. We first
evaluated technical variability in gene-level counts to en-
sure consistency with what others have reported. Next, we
evaluated the variance structure between biological repli-
cates within a treatment group, considering the functions
Var(y) =μ, kμ, and μ+φμ2 with and without normalization
and blocking factors. We believe this work will be useful
to others in analyzing and interpreting similar data.
Methods
Subjects
Twenty five study subjects representing the extremes of
the humoral immune responses to rubella vaccine (12 high
antibody responders with a median titer of 145 IU/mL
and 13 low responders with a median titer of 10 IU/mL)
were selected from a large population-based, age-stratified
random sample of 738 healthy children and young adults
(age 11 to 19 years), from Olmsted County, Minnesota.
Clinical and demographic characteristics of the population
based sample have been previously reported [8]. This
population-based candidate gene association study was
performed to assess the importance of single nucleotide
polymorphisms (SNPs) and genes involved in the immune
response heterogeneity to rubella vaccine [8-10]. All study
participants had been previously immunized with two
doses of measles-mumps-rubella (MMR-II) vaccine with a
median time since last immunization to enrollment (blood
draw and measurement of antibody levels) of 5.8 years.
The Mayo Clinic Institutional Review Board granted ap-
proval for the study. Written, informed consent and assent
from subjects and/or parents/guardians was obtained at
the time of enrollment.
PBMC culture, stimulation and RNA isolation
Subjects’ PBMC (peripheral blood mononuclear cells)
were thawed and stimulated (or left unstimulated) withlive rubella virus (multiplicity of infection, MOI= 5,
48 hrs). Total RNA was extracted from stabilized cells
using RNeasy Plus mini kit (Qiagen, Valencia, CA). RNA
concentration and quality were assessed by Nano Chip kit
analysis on an Agilent 2100 Bioanalyzer (Agilent, Palo
Alto, CA). Fifty samples from 25 subjects were completed
for culture, RNA extraction and RNA quality control with
adequate concentration and purity (lack of DNA contam-
ination), as well as good RNA integrity and lack of RNA
degradation.
Library preparation and sequencing
Libraries were prepared using the mRNA-Seq Sample
Prep Kit (Illumina, San Diego, CA) following the manu-
facturer’s instructions. Briefly, polyadenylated RNA was
isolated from 1 μg of total RNA using two rounds of
hybridization to oligo-dT magnetic beads. The mRNA
samples were chemically fragmented, reverse transcribed
and converted into double stranded cDNA. Unique Illu-
mina adaptors were ligated to the DNA fragments after
end repair (to produce blunt ends) and A-base tailing.
Fragments of approximately 200 bp were gel purified
and amplified by PCR. The libraries were validated and
quantified on an Agilent 2100 Bioanalyzer (Agilent, Palo
Alto, CA) using DNA 1000 Chip kits. Sequencing was
carried out on the Genome Analyzer GAIIx (Illumina,
San Diego, CA). Samples were sequenced as single end
reads using Illumina’s Single Read Cluster Generation kit
(v2) and 51 Cycle SBS Sequencing Kit (v3) following the
manufacturer’s instructions.
The first five flow cells were processed using Sequen-
cing Control Studio (SCS) v 2.01 and the last eight flow
cells were processed with SCS v 2.4 which allowed for
higher cluster densities and higher pass filter rates. The
images from the sequencing cycles were processed using
the Illumina Pipeline Software v1.5. Specifically, images
were converted to signal intensities using Illumina Pipe-
line’s FireCrest program. Base calling from intensity values
was performed, and the quality scores for every base were
calculated using the Bustard program. Illumina’s align-
ment tool, ELAND, was used to align the sequence reads
to genome build 36 and exon junction databases. Illumi-
na’s CASAVA tool version 1.0 was used to summarize the
alignment results using only reads that mapped to a
unique genome location and CASAVA results were
imported into Genome Studio to generate the count
tables for genes, exons, and exon-junctions. Sequencing
pass/fail quality was determined by cluster densities, per-
cent of clusters passing filters, percent of reads aligning to
the reference, and percent error rate of the alignment.
Statistical experimental design
Specimens were randomly allocated to flow cells and
lanes as follows (Figure 1A). First, one high and one low
Figure 1 Study design. A) Cartoon depicting the allocation of
subject samples to flow cells. One high (H) and one low (L)
responder was allocated to each flow cell. Within a flow cell, each
patient was randomly allocated to lanes 1-4 or 5-8, ensuring that
H/L response was balanced over lanes across all flow cells. Finally,
for each subject, two technical replicates of their stimulated and
unstimulated specimens were randomly allocated to the first two or
second two lanes such that stimulation status was balanced over
lanes. B) Flow diagram demonstrating the full initial sample set and
reasons for excluded lanes of data for the final analysis data set.
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total per flow cell), ensuring that flow cell and response
group were not confounded. Within a flow cell, the high
and low responders were randomly assigned to lanes 1-4
or 5-8 such that response status was balanced over lanes,
ensuring that lane and response group were not con-
founded. Finally, for each subject, two technical replicates
each of their stimulated and unstimulated specimens were
randomly allocated to the first two or second two lanes
such that stimulation status was balanced over lanes,
ensuring that lane and stimulation status were not
confounded.
Statistical methods
The endpoint used for analysis was total reads or counts
per gene; for the analysis of technical variation this iscounts per lane while for biological variation this is
counts summed over two technical replicate lanes. We
evaluated the suitability of the Poisson, OD Poisson, and
NB assumptions for modeling biological variability. The
Poisson distribution assumes variance is equal to the
mean μ. The OD Poisson assumes the variance increases
as a linear function of the mean, kμ, where k is a con-
stant and μ is the true mean. The NB distribution
assumes the variance increases as a quadratic function
of the mean as μ+φμ2, where φ is a constant.
Model Goodness-of-fit (GOF) was assessed via quantile-
quantile (QQ) plots of per-gene Pearson statistics Χ2 ¼Pn
i¼1 yi  y^ið Þ2=Var y^ið Þ as has been done previously [4].
Here, i indexes n samples, y is the observed count, y^i is
the predicted value and Var y^ið Þ is the appropriate vari-
ance of the predicted value (y^i for the Poisson, k^ y^i for the
OD Poisson and y^i þ ϕ^ y^i2 for the NB). This statistic is
asymptotically chi square with n-p degrees of freedom,
where n is the sample size and p is the number of model
parameters. While GOF statistics are a rather crude meas-
ure of how well a model fits, the magnitude of changes
observed here are informative. We verified that the
asymptotic assumptions were reasonable with the present
sample size in simulated NB data (Additional file 1: Figure
S1). While the empirical distributions do not have values
quite as extreme in the right tail as theoretical distribu-
tions, the deviation from the identity line is very small
relative to the distributional changes observed herein. An
alternative to the Pearson statistic is residual deviance, but
this statistic was found to be ill behaved, even in simulated
data. Such behavior has been documented previously [7].
The generalized linear model (GLM) framework was
used to fit per-gene models to test for differential ex-
pression between high and low response groups using
the log link function [7]. The most basic model
included a term for high/low response group. These
were fit to unstimulated specimens only so as to
focus on biological variation in the absence of correl-
ation between paired specimens. Counts for the two
technical replicate lanes (which we call lane-pair)
were summed for these models. Thus, these fits had
p = 1 model degree of freedom.
Model fits were evaluated with no normalization, with
total count per lane-pair, or with 75th percentile count per
lane-pair as a normalization constant [5]. Normalization
constants were included as an offset term in the GLM
model, i.e., a term with the coefficient forced to be 1.0.
The normalization offset leads to the interpretation of the
gene counts as a rate, e.g., the portion of counts out of
the total lane counts [11]. In addition, fits were evaluated
with no blocking factor or with categorical variables
added to the model to indicate flow cell (p= 13), lane-
pair (p= 4) or library preparation batch (p= 6) as block-
ing factors. These blocking factors are potential sources
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There may be global shifts in counts due to flow cell, lane
position on the flow cell such as middle versus edge, or
PCR batch effects. Lastly, per-gene, local and global vari-
ance parameter estimation strategies were evaluated.
All statistical computing was performed in R [12]. The
glm function in R was used to fit all models owing to
the flexibility in modeling biological and experimental
effects. Models based upon NB distributional assump-
tions were fit with either per-gene, moderated or global
estimates of φ. Per-gene estimates were estimated within
the glm.nb function call in the MASS package on a per-
gene basis. Global and local (moderated) estimates of φ
were computed with the edgeR package [13-16] in R. In
that package, the global estimate is computed via
quantile-adjusted conditional maximum likelihood [15]
and is shared by all genes. The local estimate is an ap-
proximate empirical Bayes estimate which shrinks per-
gene estimates towards the common global estimate
[14]. The degree of shrinkage for local estimates depends
on the prior.n parameter, where larger values result in
more shrinkage towards the global value. We evaluated
setting prior.n equal to 3, 10 (the default value), and 20;
since a prior.n of 3 yielded much better fits than 10 or
20 (data not shown), results are presented here with
prior.n = 3.
Convergence rates were excellent for all models, with
the worst case being non-convergence for four genes
when a blocking factor was included in the model. The
data have been deposited in the Gene Expression Omni-
bus and are available (with anonymous gene names
since the biological findings have not yet been published)




All 25 study subjects were female Caucasians to minimize
variation. Median rubella-specific antibody response in
the 12 high response subjects was 145 IU/ml (min 115,
max 325) and in the 13 low response subjects was
10 IU/ml (min 3, max 14) [8].
Figure 1B contains a schematic of the attempted and
failed assays. Sample libraries were prepared in seven
PCR batches and a total of thirteen flow cells were used.
Sequencing failed for all four lanes of subject 86 and for
the unstimulated lanes of subject 5361 and we did not
receive data for these lanes. For subject 86, the libraries
were determined to be of good quality and were re-
sequenced, filling the eighth flow cell; for subject 5361
the libraries were not of good quality and there was not
sufficient sample to repeat the library preparation. Since
the focus of this manuscript is on the mean-variance re-
lationship in these data in the absence of correlation, wefocus here on the 48 lanes of data corresponding to the
unstimulated specimens from 24 subjects for simplicity.
At least one count was observed for 17,337 genes. Total
counts per lane ranged from 3.7 million to 10.7 million
(Figure 2A). The wide range was due to a software up-
grade midway through the study. The distribution of
counts/gene/lane spanned five orders of magnitude as
demonstrated in Figure 2B. Sixty-two percent of the total
counts were from 10% of the genes, in both the high and
low responders (Figure 2C).
Technical variation
We assessed technical variation as the variation between
the same specimen pipetted onto two lanes of a flow cell.
Technical reproducibility in these data was good as
demonstrated by scatter and minus versus average (MVA)
plots (Additional file 1: Figure S2). Once scaled for total
lane count, virtually no linear bias was detected as
demonstrated by the grey smoother nearly overlaying the
y = 0 line. In addition, there was no hint of any nonlinear
biases as is often seen in gene expression microarray data.
This was true for all pairs of technical replicates.
QQ plots assuming Poisson-type variation were made
for all pairs of technical replicates using Pearson GOF sta-
tistics; all 24 are available in Additional file 1: Figure S3.
For Poisson-type variation, the points would be expected
to fall on the identity line. Eighteen of the plots demon-
strated variation very close to expected. Three of the plots
demonstrated a moderate fit of the Poisson distribution
with observed Pearson quantile scales ranging from ap-
proximately 25 to 50 indicating larger than expected vari-
ance. Two plots demonstrated poor fit overall as
evidenced by large observed Pearson quantile scales, one
reaching approximately 250 and the other approximately
1,200. The observed Pearson quantiles for the technical
replicates from subject 86 reached approximately 25,000.
As there were problems with this sample in the laboratory,
and because the distribution of GOF statistics was so far
from expected and so different from the others, we dis-
carded this sample from further analyses. Similar to what
others have found, we concluded that in general, technical
variation followed a Poisson distribution with variance
equal to the mean. Similar results for technical variation
were found in the stimulated specimens (data not shown).
With this conclusion we summed the per-gene counts
from the two technical replicates for further analyses as in
[4].
Biological variation
We define biological variation as the variation between
multiple subjects in the same group, e.g., high versus low
responders, cancer versus normal, treatment versus not,
etc. This variation may be small for cell lines and moder-
ate for genetically identical animals, but can be very large
Figure 2 Distributions of counts. A) Histogram of total reads per lane for 46 lanes (unstimulated specimens) on the scale of millions of reads.
B) Frequency histogram of average counts per gene per lane on the log10 scale. C) Cumulative percent of average counts per lane as a function
of the percent of genes contributing. Lines for both high (red) and low (blue) responders were drawn, but not distinguishable.
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cope with and appropriately model this variation.
In order to understand the functional form of the
mean-variance relationship, we created a scatter plot of
the sample biological variation S2 versus the sample
mean x , both calculated within high and low response
groups separately so as to estimate subject-to-subject
variability. Note that in this experiment, this variance
will include variation due to flow cell as well since there
is only one subject per response group per flow cell.
Three lines were overlaid on the points: i) an identity
line representing Poisson assumptions, ii) a linearly in-
creasing line with slope estimated from a regression ofS2 ¼ kx (no intercept) representing OD Poisson assump-
tions, and iii) a quadratic function estimated from a re-
gression of S2 ¼ xþ ϕx2 representing NB assumptions
(the slope estimate was ϕ^ ¼ 0:178). Here we show this
plot on the standard deviation scale for ease of viewing,
and with the global estimate of ϕ^ ¼ 0:131 as estimated via
the edgeR function [16] in R over all genes (Figure 3A, R
function to produce 3A provided in Additional file 2, plot-
MeanVariance.R). Unlike an identity or linear over-
dispersion function, the quadratic variance function
appeared to describe the mean-variance relationship well
for the majority of the genes. As a comparison of the ef-
fect on goodness of fit, QQ plots from models fit based on
Figure 3 Assessing presence and magnitude of over-dispersion. A) The horizontal axis indicates the mean scaled count within each of the
high/low response groups on the square root scale (labeled on the raw scale) and the vertical axis indicates the variation on the standard
deviation (i.e. square root of the variance) within each group. Each gene is thus represented by two points, one for each response group. The
green line corresponds to the Poisson assumptions, the blue line corresponds to OD Poisson assumptions, and the red line corresponds to NB
assumptions, with lines constructed as described in the text. B) Local estimates of φ from the edgeR function versus per-group mean count. The
shading indicates density of points in that area with darker shading representing higher density.
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(Figure 4A, E; R function to produce QQ plots such as
those in Figure 4 is provided in Additional file 3, fitNB-
edgeR.R). Consistent with the conclusions based on
Figure 3A, the QQ plot based on NB assumptions with φ
fixed at the edgeR global estimate of 0.131 demonstrated
dramatically improved fit overall with the observed Pearson
quantiles extending to approximately 800 (Figure 4B, F),
much less than the 300,000 for Poisson assumptions.
We questioned whether a one-size-fits-all variance
structure was appropriate. It is biologically plausible (and
many would argue likely) that the relationship, i.e. the
precise multiplier φ, varies between genes. Thus, models
were fit estimating over-dispersion on a per-gene basis
assuming a quadratic functional form. Note that the
quantities plotted in QQ plots based on the linear over-
dispersion assumption are used in the estimation of the
over-dispersion parameter in the R function and therefore
by definition were not useful for assessing model fit. The
QQ plot based on NB distributional assumptions with
per-gene estimates of φ demonstrated worse fits than
when the global estimate was used with observed Pearson
quantiles extending up 150,000 for all genes, with GOF
statistics for all but two genes below 50,000 (Figure 4C, G).
To investigate further, we exported local estimates of φ
from the edgeR function and held these fixed. These fits
demonstrated improvement over those based on the global
estimate of φ with a maximum observed Pearson Chi-
squared value of approximately 220 (Figure 4D, H). Eighty-
two percent of the local φ estimates were less than 0.15(Figure 3B). Note that a φ of 0 would correspond to no
over-dispersion, consistent with Poisson distributional
assumptions. Approximately 5% of the genes had an esti-
mate of φ greater than 0.25. Upon investigation of the
genes with φ estimates in the spike of density beginning at
a log10(average count per lane-pair) of approximately 2 and
extending to approximately 4.5 on the horizontal axis
(Figure 3B), we found that both replicates from one patient
sample had 0 counts for all of these genes. The data from
this subject otherwise appear similar to that from other
subjects. This phenomenon will be investigated further. Ig-
noring this spike, the estimates of φ do not appear to be a
function of the mean in these data. We focus on the
quadratic mean-variance functional form with local esti-
mates from here forward for four reasons. First, a quad-
ratic function fits the global mean-variance relationship
for biological variation (Figure 3A). Second, the bio-
logical interpretation of the NB distribution is appropri-
ate; count data that follow a Poisson distribution
conditional on a subject-specific mean, together with
between-subject means that follow a Gamma distribution,
give rise to the NB distribution. Third, it was clearly diffi-
cult to estimate the mean-variance relationship on a per-
gene basis (Figure 4). Fourth, we do not believe that all
genes must share the same mean-variance relationship.
Experimental variation
As in Bullard et al. [5], we found that choice of
normalization constant had little effect on GOF distri-
butions (data not shown). Therefore we present results
Figure 4 (See legend on next page.)
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Figure 4 Distribution of GOF statistics. Residual QQ plots of model fits normalized with the 75% count and no blocking factor. Tick-marks
along the top indicate deciles. The top 5% of GOF statistics are indicated in alternate colors with the top 1% being red and the next 4% being
blue. A) Standard Poisson, B) NB with a global estimate of φ, C) NB with per-gene estimates of φ, D) NB with local estimates of φ. Panels E-H are
as in A-D but zoomed in on the bottom left corner of the plots.
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Bullard et al. found this normalization scale to have less
bias in fold-change estimates and better sensitivity and
specificity than none or total lane count. The rationale
for using the 75% count to adjust for varying sequen-
cing depths rather than, say, the total lane count, is to
avoid the possibility of a high-count gene that is differ-
entially expressed being overly influential on the
normalization [5,17].
Potential sources of experimental variation examined
here were flow cell, lane-pair and library preparation
batch and all of these resulted in lower maximum
observed Pearson chi-square values which can be seen on
the QQ plots (Figure 5). Adding one of lane-pair, library
preparation batch, or flow cell to the model reduced the
maximum observed Pearson chi-squared value to about
120, 50 or approximately 25, respectively. The distribu-
tion for the library preparation batch was the closest to
the expected distribution of the three. Addition of flow
cell to the model caused the entire distribution of GOF
statistics to be smaller than expected. The largest obvious
difference between flow cells was due to the software up-
grade mid-way through the experiment. Indeed, when
models were fit without a normalization offset term, the
shift in the distribution of flow cell effect estimates corre-
sponded with the date of the SCS software upgrade mid-
way through the study which increased the number of
reads by several million per lane (Figure 6A). However,
when the total or 75th percentile offset was included,
there was no clear relationship between flow cell effect
estimates and run order (Figure 6B). From this and the
distributions of GOF statistics we concluded that some-
thing more than just a difference in lane counts could be
attributed to flow cell differences. These conclusions were
similar regardless of normalization strategy or over-
dispersion estimation strategy (data not shown).
While it is important for a model to explain all sources
of variation, a balance must be made between this and
over-fitting the data. This will especially be the case for
studies with extremely small samples which are typically
employed for next generation sequencing studies given
the intense monetary and time resource utilization.
Characterizing genes with poor model fit
We investigated whether the genes with small counts
were those with the smallest (indicative of over-fitting)
or largest (indicative of under-fitting, or not explaining
enough variation) GOF statistics when using NBdistributional assumptions with local variance estimate
and no blocking factors. Interestingly, filtering out low
count genes, even up to a total count of 10,000 (average
count 435), had only a minor impact on the distributions
(data not shown). The GOF statistics for genes averaging
less than 5 counts per subject were distributed through-
out the range of GOF statistics (red points on
Figure 7A). Further inspection of the data records
revealed two main scenarios in those genes with the
smallest GOF statistics. In the first scenario, the genes
had all zero counts in one response group versus non-
zero counts in the other response group. For genes in
the second scenario, counts within both response groups
were very consistent and had very small variance. Data
records for those genes having the largest GOF statistics
had very large variance. The distributions of counts
within the high/low response groups for one such gene
had counts spanning over two orders of magnitude in
both study groups, i.e., very large variance (Figure 7B).
Discussion
We set out to evaluate technical, biological, and experi-
mental variation in gene expression measured by mRNA-
Seq counts from n=25 subjects. Technical variation in
these data were in keeping with Poisson distributional
assumptions in general as has been reported by some
[3-5], while others have reported greater than Poisson
variation for low counts [18]. The biological variance
across all observed genes was over-dispersed relative to
the mean, increasing as a quadratic function of the mean.
This has important implications for study planning in
terms of power and sample size estimation as well as
choice of statistical modeling procedures to detect differ-
ential expression. Differential expression results were not
included here since the focus is on the mean-variance
relationship.
Over-dispersion, i.e., variance larger than the mean, is a
common phenomenon in observed count data [7]. Others
have suggested that over-dispersion in mRNA-Seq data
will likely be observed in mRNA-Seq biological replicates
and have suggested models relying on OD Poisson or NB
assumptions to account for this [5,6,13,16,19]. There
was clear evidence of over-dispersion from the standard
Poisson distribution in our data. A quadratic function
described the mean-variance relationship across all genes
better than a linear function, which is consistent with the
NB family of distributions. The interpretation of the NB
distribution as counts from several within-subject Poisson
Figure 5 (See legend on next page.)
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Figure 5 Distribution of GOF statistics when experimental factors are included in the model. QQ plots of model fits with the NB
distribution, local estimates of φ and 75th percentile count offset including blocking factors as indicated. Tick-marks along the top indicate deciles.
The top 5% of GOF statistics are indicated in alternate colors with the top 1% being red and the next 4% being blue. A) lane-pair, B) library
preparation batch, C) flow cell. Panel D is the same as A, but zoomed in on the bottom left corner of the plot; no zoom is needed for panels B
and C.
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eter makes biological sense as well in the study at hand.
In μ+φμ2, the square root of φ corresponds to the
subject-to-subject CV of the Gamma distributed Poisson
mean parameters. The CV corresponding to the global es-
timate of φ for the data presented herein is 36%. We have
observed a CV of approximately 9% for technical vari-
ation in genetically similar rats and 22% for biological
replicates in genetically similar rats (data not shown). This
is in keeping with the expectation that biological variation
is larger than technical variation, and human variation is
larger than genetically inbred animal model variation.
There are several potential sources of experimental
variation in these studies including PCR library prepar-
ation batch, flow cell, lane, and for large studies, machine
and software upgrades. Some effects can be addressed
through normalization while others must be modeled dir-
ectly. We found that normalization strategy had little im-
pact on GOF statistics. Bullard et al. [5] reported similar
results and found that the 75% count normalization
resulted in nearly no bias and the best sensitivity and spe-
cificity without increasing variance. Our data was similar
to theirs in that a small percent of the genes contributedFigure 6 Distribution of flow cell effects. Box plots of contrast coefficien
1 sorted by run order. The flow cells represented by the left four (blue) box
were analyzed with SCS v 2.4. A) Results from models without an offset to
models including the 75th percentile offset.a large portion of the counts. Thus, we chose to use the
75% count as the normalization scale in our models.
Others have evaluated normalization strategies beyond
this [17,20].
Bullard et al. found experimental variation due to li-
brary PCR preparation batch to be greater than that due
to flow cell [5]. We found that inclusion of library PCR
batch, lane-pair and flow cell each resulted in a dramatic
reduction in the large GOF statistics resulting in the GOF
statistics being too small (i.e., less than expected) in the
majority of genes. The GOF statistics were reduced to the
extent that, in this particular experiment with only one
subject per treatment per flow cell, we believe these terms
should not be included in the differential expression mod-
els in order to avoid over-fitting. Note that this experi-
ment is an incomplete block design with respect to
subject, in which case there is not complete recovery of
all effects. The discussion of incomplete recovery of
effects has spanned decades in the statistical literature.
The classic text by Scheffe points to the use of random
effects as a compromise between the extremes of not in-
cluding the effects or including them as fixed effects [21].
Since estimation in a NB model of both the dispersiont estimates indicating the difference of flow cells 2 – 13 from flow cell
es were analyzed with SCS v 2.01 while the right-most eight (red)
account for differences in total counts per lane. B) Results from
Figure 7 Understanding causes of poor model fit. A) GOF statistics for genes with an average count per subject <5 are shown in red on the
QQ plot from NB, locally estimated variance with no blocking factor models. B) Dot plot demonstrating the large variance in a gene with an
extremely large GOF statistic.
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experimental effects were modeled as fixed effects for the
purposes of this investigation.
Estimation of the over-dispersion parameter has been
the subject of much research; see for example the
summary in [15]. While the edgeR local estimates of
over-dispersion resulted in the most reasonable GOF
distributions, the results herein point to the need for fur-
ther investigation in the estimation of variance for these
data. Biologically it makes sense for the variance to differ
across genes, and that the mean-variance relationship
may vary across genes as well. For example, some sys-
tems in the body such as pH are very tightly controlled
with dramatic consequences for deviations from the
baseline normal levels. Other systems in the body such
as cholesterol are less tightly controlled, and allowed to
vary widely before consequences are observed. However,
with small sample sizes it is likely too difficult to esti-
mate the mean-variance relationship accurately and pre-
cisely on a per-gene basis. Local or per-gene estimates of
variance are common practice in gene expression micro-
array and shotgun proteomic literature [22-24]. Anders
and Huber recently presented data from two pools of
fruit fly embryos in each of two study groups that agree
with this assumption and they described a model for
variation based on NB distributional assumptions with a
“shot noise” portion and a “raw variance” portion [6]. Al-
ternatively, the fact that these model fits result in smaller
than expected GOF statistics for a majority of genes may
point to the need for a linear variance function for some
genes and quadratic variance function for others due to
biological phenomenon such as alternative splicing. In-
deed, such a modeling strategy has been proposed [25].It is difficult to compare per-gene appropriateness of
OD Poisson and NB distributional assumptions due to
the poor behavior of the residual deviance statistic and
the fact that estimation of the OD Poisson dispersion par-
ameter is a function of the Pearson statistic. Application
of a power transformation to the data in order to use
Poisson modeling assumptions has recently been pro-
posed [17]. We expect continual improvement in inform-
atics mapping algorithms to result in decreased variance;
e.g. including reads that map to multiple locations on the
genome has been shown to improve technical reproduci-
bility [26]. Robust GLMs based on M-estimators may be
an attractive alternative as well. A Gaussian approxima-
tion to the Poisson distribution is said to be valid when
the mean is ≥10 [27]; thus linear models which account
for the mean-variance relationship, e.g. via weighted least
squares, may be an attractive alternative since model fit-
ting and assessment of model fit is more straightforward
than for GLMs.
Our study had several strengths and limitations. We
reported on technical and biological variation in mRNA-
Seq data from a relatively large sample set and provide
valuable insight into biological variation that will be use-
ful to many researchers. The data herein were from true
human biological replicates rather than contrived cell line
replicates. We expect that the conclusion of a quadratic
mean-variance relationship for biological replication will
extend to other experimental settings. However, the pre-
cise estimates of over-dispersion are expected to be
study-specific; it is plausible they would be smaller in in-
bred mouse models, smaller yet in cell lines. The present
study was not designed to assess bias in estimating gene
expression, fold-changes or sensitivity and specificity of
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lized does not account for the degrees of freedom used in
estimating the dispersion parameter, thousands of data
points are used in this estimation, so the estimate should
be very stable and precise [14]. Unfortunately there was a
software upgrade mid-way through the study. Technology
in the field of next generation sequencing is progressing at
a rapid pace; indeed, data from third generation sequen-
cing is already available. This rapid pace makes upgrades,
whether in software or hardware, difficult to avoid in large
studies making it important to utilize randomization and
blocking when determining assay processing order.
Conclusions
We found that the within-gene variance structure is over-
dispersed relative to the Poisson distribution. As a result,
hypothesis tests based on Poisson distributional assump-
tions will be too liberal (reject more often than they
should) and power estimates based on these assumptions
will be over-estimated for most genes, i.e., sample sizes
will be too small for the estimated power. Local estimates
[14-16] of the mean-variance relationship are likely best,
but further research is needed to understand the optimal
variance estimation strategy. The variance increasing as a
function of the mean has implications on modeling strat-
egy even if the data are modeled as continuous values ra-
ther than counts; e.g. weighted least squares. Modeling
experimental factors within the GLM framework likely
requires larger sample sizes. These conclusions will guide
development of analytical strategies useful in study plan-
ning, accurate modeling of these data, and will aid in the
identification of true biological signals that inform our
understanding of biological systems. In addition, as with
other high dimensional expression assays [19,28-31],
since we do not yet thoroughly understand experimental
variation in next generation sequencing platforms, it is vi-
tally important to incorporate the fundamental principles
of statistical experimental design, namely biological repli-
cation, blocking and randomization, during the study de-
sign phase in order to avoid confounding of experimental
and biological signals.
Additional files
Additional file 1: Figure S1. Evaluation of asymptotic GOF
distributional assumptions. QQ plot of GOF statistics from simulated null
(i.e., no differential expression) NB data. Data for genes were simulated
with mean equal to the mean vector in the unstimulated data presented
herein, dispersion parameter equal to the edgeR estimated moderated
dispersion parameter values. GOF statistics were calculated for each gene
as described in the methods, here using the sample mean and true
dispersion parameter. Sample sizes of A) n = 1000 and B) n = 23 were
simulated in order to understand whether the asymptotic chi square
distribution was appropriate. The theoretical distributions are chi square
with A) 999 degrees of freedom and B) 22 degrees of freedom. From the
right hand tails we see that the observed distribution does not havevalues quite as extreme as those in the theoretical distribution. However,
the observed distributions are very close to the theoretical distributions
as demonstrated by most points lying on the identity line. We conclude
that the chi-square distribution is approximately correct for the data
presented herein. Additional file 1: Figure S2 – Technical reproducibility
and functional form of bias. Counts were scaled by total lane counts. A)
Representative scatter plot of technical replicate 1 versus technical replicate 2
for one subject. Spearman correlation was 0.9941 for this pair. Axes are on the
log base 2 scale. B) MVA plot for the same pair of technical replicates. The
vertical axis is difference between the counts in the two replicates on the log2
scale and the horizontal axis is the average of the two counts on the log2
scale; there is one point for each gene observed in at least one replicate. The
shading indicates density of points in that area with darker shading
representing higher density. If two replicates yielded identical results, all points
would lie on the y=0 horizontal line (indicated on the plots for reference). A
locally weighted moving average smoother is indicated to demonstrate the
average bias as a function of average count. Additional file 1: Figure S3 –
Individual QQ plots assessing distribution of technical replicates. QQ plots for
all 24 subjects for whom data was received assuming Poisson variation in
pairs of technical replicates. Vertical axes indicate observed quantiles and
horizontal axes indicate theoretical quantiles.
Additional file 2: R function to plot variance as a function of the
mean.
Additional file 3: R function to create QQ plots of Pearson GOF
statistics assuming the NB distribution.
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